Erratum: Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities(Bioorganic and Medicinal Chemistry Letters (2012) 22 (3067-3071) DOI: 10.1016/j.bmcl.2012.03.070);Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 9, 2012, Pages 3067-3071

  Chang, Minsun ^a,b   Lee, Sung Hak ^a   Kim, Ho Jun ^a,c   Koh, Jong Sung ^a,d   Kim, Aeri ^a,e  

^a LG Chemical Ltd   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d GENOSCO   (United States)

^e CHA University   (South Korea)

Author keywords

Cytochrome P450; Drug drug interaction; Farnesyl transferase inhibitor; Preclinical hepatic metabolism

Indexed keywords

CYTOCHROME P450 3A4; LB 42908; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DOG; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HAPLORHINI; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; RAT;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 84859831735     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.02.050     Document Type: Erratum

References (20)

1. D.M. Leonard J. Med. Chem. 40 1997 2971
2. R. Khosravi-Far, A. Cox, K. Kato, and C. Der Cell Growth Differ. 3 1992 461
3. K. Kato, A.D. Cox, M.M. Hisaka, S.M. Graham, J.E. Buss, and C.J. Der Proc. Natl. Acad. Sci. U.S.A. 89 1992 6403
4. T. Nagasu, K. Yoshimatsu, C. Rowell, M.D. Lewis, and A.M. Garcia Cancer Res. 55 1995 5310
5. L. Sepp-Lorenzino, Z. Ma, E. Rands, N.E. Kohl, J.B. Gibbs, A. Oliff, and N. Rosen Cancer Res. 55 1995 5302
6. S.R.D. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J.J. Perez-Ruixo, P. Palmer, and A. Howes J. Clin. Oncol. 21 2003 2492
7. C.A. Rowell, J.J. Kowalczyk, M.D. Lewis, and A.M. Garcia J. Biol. Chem. 272 1997 14093
8. M. Fouladi, H.S. Nicholson, T. Zhou, F. Laningham, K.J. Helton, E. Holmes, K. Cohen, R.A. Speights, J. Wright, and I.F. Pollack Cancer 110 2007 2535
9. J. Kauh, C. Chanel-Vos, D. Escuin, M.P. Fanucchi, R.D. Harvey, N. Saba, D.M. Shin, A. Gal, L. Pan, M. Kutner, S.S. Ramalingam, L. Bender, A. Marcus, P. Giannakakou, and F.R. Khuri Cancer 117 2011 4049
10. S.K. Lee, J.M. Kim, M.Y. Lee, K.H. Son, Y.I. Yeom, C.H. Kim, Y. Shin, J.S. Koh, D.C. Han, and B.M. Kwon Int. J. Cancer 118 2006 2172
11. H. Lee, J. Lee, S. Lee, Y. Shin, W. Jung, J.H. Kim, K. Park, K. Kim, H.S. Cho, S. Ro, S.W. Jeong, T. Choi, H.H. Chung, and J.S. Koh Bioorg. Med. Chem. Lett. 11 2001 3069
12. O. Pelkonen, M. Turpeinen, J. Uusitalo, A. Rautio, and H. Raunio Basic Clin. Pharmacol. Toxicol. 96 2005 167
13. J.B. Houston Biochem. Pharmacol. 47 1994 1469
14. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C.E. Green, C.A. Tyson, and Y. Sugiyama Pharmacol. Ther. 73 1997 147
15. M. Chiba, Y. Ishii, and Y. Sugiyama AAPS J. 11 2009 262
16. G.N. Kumar, J. Dykstra, E.M. Roberts, V.K. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G.R. Granneman Drug Metab. Dispos. 27 1999 902
17. M. Bourrie, V. Meunier, Y. Berger, and G. Fabre J. Pharmacol. Exp. Ther. 277 1996 321
18. M. Dixon Biochem. J. 55 1953 170
19. A. Cornish-Bowden Biochem. J. 137 1974 143
20. R.C. Garner, I. Goris, A.A. Laenen, E. Vanhoutte, W. Meuldermans, S. Gregory, J.V. Garner, D. Leong, M. Whattam, A. Calam, and C.A. Snel Drug Metab. Dispos. 30 2002 823